1. U.S. Food and Drug Administration.FDA approved olaparib (LYNPARZA AstraZeneca Pharmaceuticals LP) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA‐mutated (gBRCAm or sBRCAm) advanced epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to first‐line platinum‐based.https://www.fda.gov/drugs/fda-approved-olaparib-lynparza-astrazeneca-pharmaceuticals-lp-maintenance-treatment-adult-patients. Accessed January 8 2020.
2. U.S. Food and Drug Administration.FDA approves olaparib for germline BRCA‐mutated metastatic breast cancer.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer. Accessed January 8 2020.
3. Quality of life during olaparib maintenance therapy in platinum‐sensitive relapsed serous ovarian cancer;Ledermann JA;Br J Cancer,2016
4. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer
5. The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials